Le Pen Gwenaëlle, Kew James, Alberati Daniela, Borroni Edilio, Heitz Marie Paule, Moreau Jean-Luc
INSERM-EMI, Centre Paul Broca (GLP), Paris, France
Biol Psychiatry. 2003 Dec 1;54(11):1162-70. doi: 10.1016/s0006-3223(03)00374-3.
Neonatal ventral hippocampal (NVH) lesions in rats induce behavioral abnormalities at adulthood thought to simulate some aspects of the positive, negative, and cognitive deficits classically observed in schizophrenic patients. Such lesions induce a postpubertal emergence of prepulse inhibition (PPI) deficits of the startle reflex reminiscent of the sensorimotor gating deficits observed in a majority of schizophrenic patients. To study the potential involvement of the glycinergic neurotransmission in such deficits, we investigated the capacity of glycine (an obligatory N-methyl-D-aspartate [NMDA] receptor co-agonist) and ORG 24598 (a selective glycine transporter 1 inhibitor) to reverse NVH lesion-induced PPI deficits in rats.
Ibotenic acid was injected bilaterally into the ventral hippocampus of 7-day-old pups. Prepulse inhibition of the startle reflex was measured at adulthood.
Glycine (.8 and 1.6 g/kg IP) and ORG 24598 (10 mg/kg IP) fully and partially reversed lesion-induced PPI deficits, respectively.
These findings confirm that an impaired glutamatergic neurotransmission may be responsible for PPI deficits exhibited by NVH-lesioned rats and support the hypoglutamatergic hypothesis of schizophrenia. They also suggest that drugs acting either directly at the NMDA receptor glycine site or indirectly on the glycine transporter 1 could offer promising targets for the development of novel therapies for schizophrenia.
大鼠新生期腹侧海马(NVH)损伤会导致成年后出现行为异常,这些异常被认为模拟了精神分裂症患者经典观察到的阳性、阴性和认知缺陷的某些方面。此类损伤会导致青春期后惊跳反射的前脉冲抑制(PPI)缺陷出现,这类似于大多数精神分裂症患者中观察到的感觉运动门控缺陷。为了研究甘氨酸能神经传递在此类缺陷中的潜在作用,我们研究了甘氨酸(一种必需的N-甲基-D-天冬氨酸[NMDA]受体共激动剂)和ORG 24598(一种选择性甘氨酸转运体1抑制剂)逆转NVH损伤诱导的大鼠PPI缺陷的能力。
向7日龄幼崽的腹侧海马双侧注射鹅膏蕈氨酸。在成年期测量惊跳反射的前脉冲抑制。
甘氨酸(0.8和1.6 g/kg腹腔注射)和ORG 24598(10 mg/kg腹腔注射)分别完全和部分逆转了损伤诱导的PPI缺陷。
这些发现证实,谷氨酸能神经传递受损可能是NVH损伤大鼠出现PPI缺陷的原因,并支持精神分裂症的低谷氨酸能假说。它们还表明,直接作用于NMDA受体甘氨酸位点或间接作用于甘氨酸转运体1的药物可能为开发新型精神分裂症治疗方法提供有前景的靶点。